本システムでは、JavaScriptを利用しています。JavaScriptを有効に設定してからご利用ください。

【参】六角形画像(IR Information)

H1

IR Library

パンくずリスト

ホーム > Kidswell Bio Corporation > IR Information > IR Library

コンテンツ

IR Library

★IR：カテゴリメニュー

IR Library

2022/02/04

[Presentation] Financial Results for the Third Quarter of FY2021 [PDF：1670KB]
2022/02/04

Summary of Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2022
[PDF：469KB]
2022/01/26

Announcement of business alliance agreement with Metcela Inc. for the regenerative medicine business [PDF：207KB]
2021/12/09

Announcement of the launch of Ranibizumab BS [PDF：120KB]
2021/11/25

Company note 2Q update from OMEGA Investment [PDF：274KB]
2021/11/05

Summary of Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2021 [PDF：470KB]
2021/11/05

[Presentation] Financial Results for the Second Quarter of FY2021 [PDF：2373KB]
2021/10/21

Announcement of extraordinary income (gain on sale of investment securities) and revisions of the consolidated financial forecast for the FY 2021 [PDF：191KB]
2021/09/28

Company Research and Analysis Report from OMEGA Investment [PDF：4959KB]
2021/09/27

Announcement of Receiving Manufacturing and Sales Approval for biosimilar in the Ophthalmic Area in Japan [PDF：119KB]
2021/09/08

Announcement of collaborative research agreement with NanoCarrier Co., Ltd. for development of a designer cell as reinforced cell therapy utilizing SHED [PDF：251KB]
2021/08/12

[Presentation] Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2022 [PDF：2274KB]
2021/08/12

Summary of Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2022 [PDF：456KB]
2021/05/17

Summary of Consolidated Financial Results for the Fiscal Year Ended March 31, 2021 [PDF：435KB]
2021/02/15

Summary of Our Mid-Term Strategic Plan from FY2021 to FY2025 [PDF：1678KB]
2021/01/22

Our mid-term strategic plan will be announced on Feb. 15.
2021/01/05

Interview video of Masaharu Tani, CEO, has been released at Sessa TV.
2020/11/09

Summary of Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2021 [PDF：596KB]
2020/11/09

FY2020 2Q IR Meeting Information [PDF：3730KB]
2020/09/18

Announcement of Application for Approval of Manufacturing and Sales in Japan for biosimilar in the Ophthalmic Area [PDF：254KB]
2020/08/20

Announcement of Joint Research Agreement with Hokkaido University and Spinal Injuries Center for Non-Union Fractures [PDF：255KB]
2020/07/15

New business alliance with Dojin Group to accelerate research and development of regenerative medicine products by using SHED and expand SHED-related business [PDF：631KB]
2020/05/25

Summary of Consolidated Financial Results for the Fiscal Year Ended March 31, 2020 [PDF：480KB]
2020/05/25

FY2019 IR Meeting Information [PDF：1450KB]
2020/04/08

Announcement of completion of issuance of the 3rd series of convertible bond with stock acquisition rights and the 10th series of stock acquisition rights [PDF：336KB]
2020/03/23

[Presentation] Establishment of manufacturing process for the master cell bank and business alliance with Mochida Pharma, and Financing for driving JRM-001 [PDF：763KB]
2020/03/16

Announcement of Establishment of Manufacturing Process for Master Cell Bank Based on the Business Partnership with NIKON CORPORATION

[PDF：122KB]
2020/03/05

Announcement of Joint Research Agreement with Oita University for Peripheral Nerve Paralysis [PDF：176KB]
2020/03/05

Announcement of Joint Research Agreement with Nagoya University for Spinal Cord Injury [PDF：146KB]
2020/02/19

End of Observation Period for the Last Patient in Phase III Clinical Trial of Biosimilar Product for Ophthalmic Treatment in Japan Developed with Senju Pharmaceutical Co., Ltd.

[PDF：128KB]
2020/02/17

[Presentation] Announcement of Acquisition of Shares of Japan Regenerative Medicine Co., Ltd. [PDF：763KB]
2020/02/17

[Document] Announcement of Acquisition of Shares of Japan Regenerative Medicine Co., Ltd. [PDF：182KB]
2020/02/14

Announcement of Business Alliance Agreement with DOJIN GROUP Co, Ltd. for business development in regenerative medicine and healthcare area [PDF：124KB]
2020/02/05

FY2019 3Q IR Meeting Information [PDF：1828KB]
2020/02/05

Summary of Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2020
[PDF：309KB]
2020/01/30

Signed alliance agreement with Eil for business development in regenerative medicine and healthcare area [PDF：115KB]
2020/01/22

Announcement of Joint Research Agreement for Cerebral Palsy with Three Institutes

[PDF：189KB]
2020/01/21

Announcement of Joint Research Agreement for New Antibodies with MabGenesis Inc.

[PDF：182KB]
2020/01/06

Announcement of Joint Development Agreement with Sapporo Medical University

[PDF：271KB]
2019/12/02

Announcement of Joint Development Agreement of Aflibercept Biosimilars with Kishi Kasei Co., Ltd.

[PDF：319KB]
2019/11/05

FY2019 2Q IR Meeting Information [PDF：1547KB]
2019/11/05

Summary of Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2020 [PDF：341KB]
2019/11/05

Announcement of the Appointment of Scientific Advisor and Establishment of Scientific Advisory Board [PDF：243KB]
2019/11/05

Announcement of Academia-industry Collaboration with Showa University School of Medicine for a Development of Treatments in Cell Therapy Field using Stem Cells from Human Exfoliated Deciduous Teeth [PDF：138KB]
2019/10/16

Acquisition and Cancellation of the 6th Series of Stock Acquisition Rights (Private Placement) [PDF：130KB]
2019/10/07

Signed a Contract for Sale of Stem Cells from Human Exfoliated Deciduous Teeth between Kidswell Bio Corporation Co., Ltd.and Summit Pharmaceuticals International Corporation.

[PDF：151KB]
2019/09/30

New Financing Arrangements and Investment in Heartseed Inc.

[PDF：863KB]
2019/09/30

Announcement of Investment in Regenerative Medicine Venture Company Heartseed Inc.

[PDF：116KB]
2019/09/20

Announcement of Receiving Manufacturing and Marketing Approval for Darbepoetin Alpha Biosimilars in Japan

[PDF：111KB]
2019/09/18

Announcement of Joint Research Agreement with Gifu Pharmaceutical University for a Development of Treatments for an Ophthalmologic Disease using Stem Cells from Human Exfoliated Deciduous Teeth [PDF：107KB]

前へ
1
2
3
4
次へ